Date: 2018-01-29
Type of information: Nomination
Compound: chief medical officer
Company: Ultragenyx Pharmaceutical (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 29, 2018, Ultragenyx Pharmaceutical announced that it has appointed Camille L. Bedrosian, M.D. as Executive Vice President and Chief Medical Officer. In this role, Dr. Bedrosian will provide strategic leadership to the clinical development and translational research programs, and will oversee Medical Affairs, Global Clinical Development groups, Clinical Operations and Drug Safety/Pharmacovigilance. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team. Most recently, Dr. Bedrosian was Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals. During her ten years at Alexion, Dr. Bedrosian provided leadership for the development of drugs and drug candidates including those designed to address devastating rare diseases caused by defects in the complement system including Soliris® (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Prior to Alexion, Dr. Bedrosian spent more than five years as the Chief Medical Officer for Ariad Pharmaceuticals, Inc., where she provided leadership for drug development, built the clinical organization and participated in the partnership with Merck for Ariad's small molecule mTOR inhibitor. Before joining Ariad, Dr. Bedrosian served from 1997 to 2002 in the Clinical Research and Development Department of Genetics Institute, (acquired by Wyeth, now part of Pfizer), where she assumed roles of increasing responsibility and became therapeutic area head for hemophilia.
- Dr. Bedrosian was an Assistant Professor of Medicine at Duke University Medical Center and member of the Duke Comprehensive Cancer Center, where she also had completed her residency in internal medicine and fellowship training in hematology and medical oncology. Dr. Bedrosian holds an A.B. degree in Honors Chemistry from Harvard University, an M.D. degree from Harvard Medical School and an M.S. degree in Biophysics from the Massachusetts Institute of Technology. She currently serves as Member of the MIT Corporation Visiting Committee for the Department of Biology.
Financial terms:
Latest news:
Is general: Yes
